Endocrine Aspects of Duchenne Muscular Dystrophy

Neuromuscular Disorders

Volumn 21, Issue 4, 2011, Pages 298-303

  Bianchi, Maria Luisa ^a   Biggar, Doug ^b   Bushby, Kate ^c   Rogol, Alan D ^d   Rutter, Meilan M ^e   Tseng, Brian ^f  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CORTICOSTEROID; DEFLAZACORT; HUMAN GROWTH HORMONE; METFORMIN; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PREDNISONE; RECOMBINANT GROWTH HORMONE; RISEDRONIC ACID; SOMATOMEDIN C; TESTOSTERONE; ZOLEDRONIC ACID;

ARTICLE; BODY MASS; BONE DENSITY; BONE METABOLISM; CONTINUOUS INFUSION; CORRELATIONAL STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIET RESTRICTION; DIETARY INTAKE; DOSE RESPONSE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; DUCHENNE MUSCULAR DYSTROPHY; ENDOCRINE DISEASE; FRAGILITY FRACTURE; GLUCOSE INTOLERANCE; GLYCEMIC INDEX; GROWTH DISORDER; GROWTH HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPOGONADOTROPIC HYPOGONADISM; INSULIN RESISTANCE; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PRIORITY JOURNAL; PUBERTY DISORDERS; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; BONE AND BONES; ENDOCRINE GLANDS; FEMALE; GROWTH; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PUBERTY; WEIGHT GAIN;

EID: 79952740316     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2011.02.006     Document Type: Article

References (30)

1. Rudman D., Chyatte S.B., Patterson J.H., et al. Metabolic effects of human growth hormone and of estrogens in boys with Duchenne muscular dystrophy. J Clin Invest 1972, 51:1118-1124.
2. Zatz M., Betti R.T. Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency: a five years follow-up. Am J Med Genet 1986, 24:567-572.
3. Griggs R.C., Moxley R.T., Mendell J.R., et al. Randomized, double-blind trial of mazindol in Duchenne dystrophy. Muscle Nerve 1990, 13:1169-1173.
4. Lynch G.S. Therapies for improving muscle function in neuromuscular disorders. Exerc Sport Sci Rev 2001, 29:141-148.
5. Nagel B.H.P., Mortier W., Elmlinger M., Wollmann H.A., Schmitt K., Ranke M.B. Short stature in Duchenne muscular dystrophy: a study of 34 patients. Acta Paediatr 1999, 88:62-65.
6. Allen D.B., Julius J.R., Breen T.J., Attie K.M. Treatment of glucocorticoid-induced growth suppression with growth hormone. National cooperative growth study. J Clin Endocrinol Metab 1998, 83:2824-2829.
7. Wong B., Rutter M., Rose S., et al. Growth Hormone Therapy in Duchenne Muscular Dystrophy. Best Evidence Statement 2009, CCHMC online publication.
8. Frank G.R., Smith R.E. Effective growth hormone therapy in a growth hormone deficient patient with Duchenne muscular dystrophy without evidence of acceleration of the dystrophic process. J Pediatr Endocrinol Metab 2001, 14:211-214.
9. Cittadini A., Ines Comi L., Longobardi S., et al. A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies. Eur Heart J 2003, 24:664-672.
10. Rutter MM, Collins J, Woo J, et al. Growth hormone improves growth in Duchenne muscular dystrophy boys with steroid-induced growth failure. Abstract, presented at the Endocrine Society 92nd Annual Meeting, San Diego; 2010.
11. Shavlakadze T., White J., Hoh J.F., Rosenthal N., Grounds M.D. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Mol Ther 2004, 10:829-843.
12. Gregorevic P., Plant D.R., Leeding K.S., Bach L.A., Lynch G.S. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am J Pathol 2002, 161:2263-2272.
13. Gregorevic P., Plant D.R., Lynch G.S. Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. Muscle Nerve 2004, 30:295-304.
14. Rutter MM, Wong BL, Rose SR, et al. Metformin improves weight gain and body mass index in Duchenne Muscular Dystrophy. Poster presentation, Pediatric Academic Societies Annual Meeting, Baltimore, USA (2009), and 14th International Congress of the World Muscle Society, Geneva, Switzerland; 2009.
15. Carter D.R., Bouxsein M.L., Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992, 7:135-137.
16. Mølgaard C., Thomsen B.L., Prentice A., Cole T.J., Michaelsen K.F. Whole body bone mineral content in healthy children and adolescents. Arch Dis Child 1997, 76:9-15.
17. Henderson R.C., Lin P.P., Greene W.B. Bone mineral density in children and adolescents who have spastic cerebral palsy. J Bone Joint Surg Am 1995, 77:1671-1681.
18. Goulding A., Cannan R., Williams S.M., Gold E.J., Taylor R.W., Lewis-Barned N.J. Bone mineral density in girls with forearm fractures. J Bone Miner Res 1998, 13:143-148.
19. Clark E.M., Ness A.R., Bishop N.J., Tobias J.H. Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res 2006, 21:1489-1495.
20. van Staa T.P., Cooper C., Leufkens H.G., Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003, 18:913-918.
21. King W.M., Ruttencutter R., Nagaraja H.N., et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007, 68:1607-1613.
22. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med 1998, 339:292-299.
23. Reid D.M., Devogelaer J.P., Saag K., et al. HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-1263.
24. Bianchi M.L., Cimaz R., Bardare M., et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000, 43:1960-1966.
25. Saag K.G., Shane E., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
26. Li C.Y., Price C., Delisser K., Nasser P., et al. Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis. J Bone Miner Res 2005, 20:117-124.
27. Henderson R.C., Lark R.K., Kecskemethy H.H., Miller F., Harcke H.T., Bachrach S.J. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002, 141:644-651.
28. Allington N., Vivegnis D., Gerard P. Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta Orthop Belg 2005, 71:91-97.
29. McKay H., Smith E. Winning the battle against childhood physical inactivity: the key to bone strength?. J Bone Miner Res 2008, 23:980-985.
30. Gilsanz V., Wren T.A., Sanchez M., Dorey F., Judex S., Rubin C. Low-level, high-frequency mechanical signals enhance musculoskeletal development of young women with low BMD. J Bone Miner Res 2006, 21:1464-1474.